Management of Non-Muscle Invasive Bladder Cancer (Part 1): High Risk
Doctors Kamat, Hensley, and Shore use professional experience and guidelines to discuss high-risk NMIBC.

Introduction

Management of Non-Muscle Invasive Bladder Cancer

Part 1: High Risk NMIBC

Part 2: Low and Intermediate Risk NMIBC

Diagnosis and Staging of Bladder Cancer

Treatment Considerations with BCG

Surveillance and Standard Biomarkers

This educational video series is brought to you by Janssen Biotech, Inc., and is not certified for continuing medical education. The consultants have been paid an honorarium by Janssen Biotech, Inc. The speakers are presenting on behalf of Johnson & Johnson and must present information in compliance with FDA requirements applicable to Johnson & Johnson. These presentations were produced in collaboration with IBCG and Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.